|
🐜
|
Screening and prostate-cancer mortality in a randomized European study.
23 auth.
F. Schröder,
J. Hugosson,
M. Roobol,
T. Tammela,
S. Ciatto,
V. Nelen,
M. Kwiatkowski,
M. Luján,
H. Lilja,
M. Zappa,
...
L. Denis,
F. Recker,
A. Berenguer,
L. Määttänen,
C. Bangma,
G. Aus,
A. Villers,
X. Rébillard,
T. H. van der Kwast,
B. G. Blijenberg,
S. Moss,
H. D. de Koning,
A. Auvinen
|
11 |
2009 |
11
🐜
|
|
🦁
|
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.
24 auth.
H. D. de Koning,
C. van der Aalst,
P. D. de Jong,
E. Scholten,
K. Nackaerts,
M. Heuvelmans,
J. Lammers,
C. Weenink,
U. Yousaf-Khan,
N. Horeweg,
...
S. van 't Westeinde,
M. Prokop,
W. Mali,
F. M. Mohamed Hoesein,
P. V. van Ooijen,
J. Aerts,
M. D. den Bakker,
E. Thunnissen,
J. Verschakelen,
R. Vliegenthart,
J. Walter,
K. ten Haaf,
H. Groen,
M. Oudkerk
|
10 |
2020 |
10
🦁
|
|
🐜
|
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.
18 auth.
M. Kriege,
C. Brekelmans,
C. Boetes,
Peter E. Besnard,
H. Zonderland,
I. Obdeijn,
R. Manoliu,
T. Kok,
H. Peterse,
M. Tilanus-Linthorst,
...
S. Muller,
S. Meijer,
J. Oosterwijk,
L. Beex,
R. Tollenaar,
H. D. de Koning,
E. Rutgers,
J. Klijn
|
10 |
2004 |
10
🐜
|
|
🐜
|
Prostate-cancer mortality at 11 years of follow-up.
29 auth.
F. Schröder,
J. Hugosson,
M. Roobol,
T. Tammela,
S. Ciatto,
V. Nelen,
M. Kwiatkowski,
M. Luján,
H. Lilja,
M. Zappa,
L. Denis,
F. Recker,
Á. Páez,
L. Määttänen,
C. Bangma,
...
G. Aus,
S. Carlsson,
A. Villers,
X. Rébillard,
T. H. van der Kwast,
P. Kujala,
B. G. Blijenberg,
U. Stenman,
A. Huber,
K. Taari,
M. Hakama,
S. Moss,
H. D. de Koning,
A. Auvinen
|
10 |
2012 |
10
🐜
|
|
🐢
|
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.
7 auth.
G. Draisma,
R. Boer,
S. Otto,
I. W. van der Cruijsen,
R. Damhuis,
F. Schröder,
...
H. D. de Koning
|
10 |
2003 |
10
🐢
|
|
🐢
|
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
8 auth.
G. Draisma,
Ruth Etzioni,
A. Tsodikov,
A. Mariotto,
E. Wever,
R. Gulati,
...
E. Feuer,
H. D. de Koning
|
9 |
2009 |
9
🐢
|
|
🐢
|
Management of lung nodules detected by volume CT scanning.
27 auth.
R. V. van Klaveren,
M. Oudkerk,
M. Prokop,
E. Scholten,
K. Nackaerts,
R. Vernhout,
C. V. Van Iersel,
K. V. D. van den Bergh,
S. van 't Westeinde,
C. van der Aalst,
E. Thunnissen,
Dong Xu,
Ying Wang,
Yingru Zhao,
H. Gietema,
...
B. de Hoop,
H. Groen,
G. D. de Bock,
P. V. van Ooijen,
C. Weenink,
J. Verschakelen,
J. Lammers,
W. Timens,
D. Willebrand,
A. Vink,
W. Mali,
H. D. de Koning
|
9 |
2009 |
9
🐢
|
|
🐜
|
Risk‐based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch‐Belgian randomised lung cancer multi‐slice CT screening trial (NELSON)
10 auth.
C. V. Van Iersel,
H. D. de Koning,
G. Draisma,
W. Mali,
E. Scholten,
K. Nackaerts,
...
M. Prokop,
J. Habbema,
M. Oudkerk,
R. V. van Klaveren
|
9 |
2007 |
9
🐜
|
|
🐜
|
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
31 auth.
J. Hugosson,
M. Roobol,
M. Månsson,
T. Tammela,
M. Zappa,
V. Nelen,
M. Kwiatkowski,
M. Luján,
S. Carlsson,
K. Talala,
H. Lilja,
L. Denis,
F. Recker,
Á. Páez,
D. Puliti,
...
A. Villers,
X. Rébillard,
T. Kilpeläinen,
U. Stenman,
R. Godtman,
K. Stinesen Kollberg,
S. Moss,
P. Kujala,
K. Taari,
A. Huber,
T. H. van der Kwast,
E. Heijnsdijk,
C. Bangma,
H. D. de Koning,
F. Schröder,
A. Auvinen
|
8 |
2019 |
8
🐜
|
|
🐜
|
European position statement on lung cancer screening.
22 auth.
M. Oudkerk,
A. Devaraj,
R. Vliegenthart,
T. Henzler,
H. Prosch,
C. Heussel,
G. Bastarrika,
N. Sverzellati,
M. Mascalchi,
S. Delorme,
...
D. Baldwin,
M. Callister,
N. Becker,
M. Heuvelmans,
W. Rzyman,
M. Infante,
U. Pastorino,
J. Pedersen,
E. Paci,
S. Duffy,
H. D. de Koning,
J. Field
|
8 |
2017 |
8
🐜
|
|
🐜
|
Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening.
17 auth.
N. Horeweg,
J. van Rosmalen,
M. Heuvelmans,
C. van der Aalst,
R. Vliegenthart,
E. Scholten,
K. ten Haaf,
K. Nackaerts,
J. Lammers,
C. Weenink,
...
H. Groen,
P. V. van Ooijen,
P. D. de Jong,
G. D. de Bock,
W. Mali,
H. D. de Koning,
M. Oudkerk
|
8 |
2014 |
8
🐜
|
|
🐜
|
Overdiagnosis in Mammographic Screening for Breast Cancer in Europe: A Literature Review
7 auth.
D. Puliti,
S. Duffy,
G. Miccinesi,
H. D. de Koning,
E. Lynge,
M. Zappa,
...
E. Paci
|
8 |
2012 |
8
🐜
|
|
🐢
|
Quality-of-life effects of prostate-specific antigen screening.
22 auth.
E. Heijnsdijk,
E. Wever,
A. Auvinen,
J. Hugosson,
S. Ciatto,
V. Nelen,
M. Kwiatkowski,
A. Villers,
Á. Páez,
S. Moss,
...
M. Zappa,
T. Tammela,
T. Mäkinen,
S. Carlsson,
I. Korfage,
M. Essink‐bot,
S. Otto,
G. Draisma,
C. Bangma,
M. Roobol,
F. Schröder,
H. D. de Koning
|
8 |
2012 |
8
🐢
|
